Interview with the Head of Research and Development, Dr. Claudia Mattern, PhD, adj. Professor Chief Science Officer MetP Pharma AG Action (Protection) instead of Reaction in viral airway invasion. Emmetten, Switzerland, 28 January 2021 MetP Pharma AG is a R&D company focused exclusively on nasal application; whose technology represents a real advance in the application of brain-acting molecules. This development is optimally suited to ensure transport to the brain and spinal